|Day Low/High||95.00 / 95.84|
|52 Wk Low/High||58.59 / 97.07|
Investors in biotech stocks appear to be happy with a Trump win and Mizuho's senior biotech analyst says companies in the sector could continue to climb in 2017.
The consideration of the contrary has been a theme all week. And here in "Don't Run With the Crowd: Embrace the Contrary." Miami madness (of a real estate kind) Mark Grant is scared by our currency's strength. Danielle on scenarios. Booc...
It looks like CELG could retest the highs around $140.
At the end of the day! Don't run with the crowd: Embrace contrary and second-level thinking instead. Extreme policy uncertainty. More Howard Marks. Less Bill Miller. My little sister! Graf wrote a goodie. The movie was in revers...
"Today I am asking myself ... Did the FANG names just peak the way iShares NASDAQ Biotechnology Index ETF IBB did in 2015 and Energy Select Sector SPDR ETFXLE did in 2014? The S&P 500 Index kept rising, but those two groups were done!" -- Kass Diar...
U.S. stocks rallied slightly in midday trading as energy, financials, and healthcare sectors saw green on Wednesday following the surprise election of Republican Donald Trump.
The market isn't buying that Trump is bad for business
Momentum is very good here and relative strength has improved greatly.
Our job now is to digest the news, shake off the emotions and find a way to benefit from it.
It has real earnings, not some artificial, buyback-supported junk.
"Dougie, take what Mr. Market gives you." -- Grandma Koufax And I did, Grandma Koufax. A consecutive nine-day market drop was snapped as we regained most that was lost in that period. Today was a great day. (Boy, would I like to annualize the pe...
After the election passes we are going to talk about companies again -- and these have done well.
That's because the big issue is how to put capital to work.
Some potential positives today: Strength in the Russell Index. Improving breadth. Improving Clinton odds by "538" and the London betting parlors. A great deal of pushback to my idea of a trading rally. Turnaround in large-cap biotech (Allergan , Cel...
Four Large Cap Stocks Ready to Rebound: Home Depot, Celgene, Charles Schwab and Allergan
The downdraft may reflect investors and traders view that Trump will win.
"It's not a joke, it's a rope, Tuco. Now I want you to get up there and put your head in that noose." -- Blondie in "The Good, the Bad and the Ugly." I did very little today, save adding to my bank/financial shorts. I moved back to Market Neutral. ...
Such unwarranted fears have depressed the sector, which could bounce back after Nov. 8.
Biotech Omeros and builder LGI Homes both seem substantially undervalued given their prospects.
The longer we go without much progress, the more inclined players are to move to the sidelines.
This is what we need to stop treading water and move this market to a tradable low.
A short "Takeaways" today as I have to prepare for some morning meetings. Down, up, down -- in a relatively volatile session. I am comfortable with yesterday's bearish moves. I sold more (short) today on the surprising (at least to me!) ramp...
Don't get excited by Take Under Monday. The technical picture is mixed. A stronger U.S. dollar presents multi-national vulnerability. This is consistent with Goldman Sachs lowering their three-year S&P 500 profits picture. Peak Sports Viewer...
The likely continuation of a split government should help the sector recover from its recent beat-down.
This sector is one of the few areas of the market where you'll find myriad compelling values.
Celgene's days of stellar growth will continue to stretch far into the future.